

Date: March 5, 2025

To,
The General Manager,
Department of Corporate Services,
BSE Ltd.,
1st Floor, New Trading Ring,
Rotunda Building,
P.J. Towers,
Dalal Street, Fort,
Mumbai – 400 001

BSE Code - 975354

Dear Sir,

Sub: - Intimation under Regulation 51 read with Part B of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") and other applicable provisions

Pursuant to Regulation 51 read with Part B of Schedule III of the SEBI Listing Regulations and other applicable provisions, we wish to inform you that the Board of Directors of the Company, at its Meeting held today, i.e. Wednesday, March 5, 2025, has inter alia, considered and approved the appointment of Mr. Suresh Kalra, as the Chief Executive Officer of the Company with immediate effect.

The requisite details pertaining to the appointment of the Key Managerial Personnel (KMPs) pursuant to the SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/ P/CIR/2023/123 dated July 13, 2023, is enclosed as Annexure A.

We request you to take the afore-mentioned information in record and oblige.

Yours faithfully,

For Aquapharm Chemical Limited

Jayesh Damle Company Secretary and Compliance Officer



## 'Annexure A'

Approved the appointment of Mr. Suresh Kalra, as the Chief Executive Officer of the Company with immediate effect.

Details under SEBI Circular No. SEBI/HO/CFD/CFD-PoD-l/P/CIR/2023/123 dated July 13, 2023:

Sr. No.	Particulars	Details
1. 1.	Name	Mr. Suresh Kalra
2.	reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Appointment of Mr. Suresh Kalra as the Chief Executive Officer of the Company
3.	Date of appointment / <del>reappointment/cessation</del> (as applicable) & term of appointment/ <del>re-appointment;</del>	With effect from March 5,2025
4.	Brief profile (in case of appointment);	Mr. Suresh Kalra (aged 51 years) holds a degree in Engineering and Business Management and has overall experience of more than 26 years in leading global business with expertise in business strategy, operational efficiency and building organisational capability.
5.	Disclosure of relationships between directors (in case of appointment of a director).	N.A.